Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

Cedrol promotes hair growth better than baricitinib by regulating immune cells.

This review highlights the variability and unpredictability of alopecia areata, ranging from single scalp patches to total body hair loss, and notes the 2022 approval of the first AA-specific drug, baricitinib, potentially spurring new research into targeted treatments.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

In this study with mouse follicle stem cells, astraglus polysaccharide increased markers of cell proliferation and gene expression, suggesting a potential mechanism for treating alopecia and promoting hair growth.

This review discusses the evaluation, clinical presentation, and cutaneous manifestations of congenital adrenal hyperplasia, focusing on differential diagnosis challenges with polycystic ovary syndrome, and reports no new clinical findings.

In this study, researchers described hyperandrogenism as a condition resulting from excessive androgen production, which can lead to symptoms like acne, hirsutism, and hair loss, particularly relevant for dermatological evaluation and management in adult females.

In this study, hair anomalies associated with acrodermatitis enteropathica in a young girl improved significantly after two years of zinc therapy.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

Lower acetylation makes chitin nanofibers thinner and more suitable for various uses.

This study describes the successful management of Andean bear alopecia syndrome in three female bears using oclacitinib, leading to rapid pruritus resolution and fur regrowth without adverse effects.

This study reports the first case of atrichia with papular lesions in a Taiwanese family without a detectable mutation in the HR gene.

In this study on patchy alopecia areata treatment involving 20 patients, TCA (triamcinolone acetonide) injections showed a significantly better response and minimal side effects compared to superficial cryotherapy.

This study found that abrocitinib showed promising efficacy and safety in adolescents with moderate-to-severe alopecia areata, with significant hair regrowth observed over 10 months of treatment.

Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.

This study found that a single injection of autologous cell micrografts significantly improved hair condition in women with androgenetic alopecia six months post-treatment.

According to this study, systemic retinoids, specifically oral isotretinoin and acitretin, were more effective than finasteride in stabilizing the frontal hairline in female patients with frontal fibrosing alopecia, achieving treatment goals in over 70% of cases.

This report describes a case of Birt-Hogg-Dube syndrome with manifestations including multiple fibrofolliculomas, acrochordons, and renal oncocytoma.

This source suggests that alitretinoin may be a safe and potentially effective treatment for patients with mild to moderate alopecia areata not responding to conventional therapies, though further research is needed to confirm its role, either alone or as an adjunct.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

This study hypothesizes that postinflammatory hyperpigmentation in ashy dermatosis may result from basal cell apoptosis, as evidenced by consistent histologic findings across nine patients.

In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

This article discusses the phases and histological features of alopecia areata and reports no new clinical findings; the authors emphasize recognizing these phases for accurate diagnosis.

This case report details atrichia with papular lesions in a 4-year-old girl, highlighting specific histological findings on her scalp and other affected areas.

This study developed a grooved microneedle platform enabling precise transdermal delivery of triamcinolone acetonide for alopecia areata, achieving accurate dosing by controlling groove position and drug concentration.